Last reviewed · How we verify

Placebo (for Aspirin 300)

Assistance Publique - Hôpitaux de Paris · Phase 3 active Small molecule

Placebo (for Aspirin 300) is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Control arm in Phase 3 trial comparing Aspirin 300 efficacy and safety. Also known as: Placebo300.

Placebo has no active pharmacological mechanism; it serves as an inert control in clinical trials to establish baseline efficacy and safety of the active comparator (Aspirin 300).

Placebo has no active pharmacological mechanism; it serves as an inert control in clinical trials to establish baseline efficacy and safety of the active comparator (Aspirin 300). Used for Control arm in Phase 3 trial comparing Aspirin 300 efficacy and safety.

At a glance

Generic namePlacebo (for Aspirin 300)
Also known asPlacebo300
SponsorAssistance Publique - Hôpitaux de Paris
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Placebo is a non-therapeutic substance used in randomized controlled trials to provide a blinded control arm. Any observed effects in the placebo group represent natural disease progression, regression to the mean, or the placebo effect itself. This allows researchers to isolate the true pharmacological effects of Aspirin 300 by comparison.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo (for Aspirin 300)

What is Placebo (for Aspirin 300)?

Placebo (for Aspirin 300) is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris, indicated for Control arm in Phase 3 trial comparing Aspirin 300 efficacy and safety.

How does Placebo (for Aspirin 300) work?

Placebo has no active pharmacological mechanism; it serves as an inert control in clinical trials to establish baseline efficacy and safety of the active comparator (Aspirin 300).

What is Placebo (for Aspirin 300) used for?

Placebo (for Aspirin 300) is indicated for Control arm in Phase 3 trial comparing Aspirin 300 efficacy and safety.

Who makes Placebo (for Aspirin 300)?

Placebo (for Aspirin 300) is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

Is Placebo (for Aspirin 300) also known as anything else?

Placebo (for Aspirin 300) is also known as Placebo300.

What development phase is Placebo (for Aspirin 300) in?

Placebo (for Aspirin 300) is in Phase 3.

Related